Letter: Methodological Considerations in Comparing Liver Outcomes of Glucagon‐Like Peptide‐1 Receptor and Sodium Glucose Cotransporter‐2 Inhibitors

Documenti analoghi

• Letter: Crohn's Disease or Comorbidity? Reassessing Opioid Prescribing Patterns
  di: Kuan‐Ju Lin, et al.
  Pubblicazione: (2025)
• Impact of GLP‐1 Receptor Agonists on Alcohol‐Related Liver Disease Development and Progression in Alcohol Use Disorder
  di: Chia‐Chih Kuo, et al.
  Pubblicazione: (2025)
• Some Risks of Gastrointestinal Adverse Events Associated With Glucagon‐Like PEPTIDE‐1 Receptor Agonists Are Likely Explained by BMI
  di: Benjamin Douglas Liu, et al.
  Pubblicazione: (2025)
• Editorial: Immune Checkpoint Inhibitors and HBV Reactivation in Liver Cancer—Reassurance With Vigilance
  di: Romeo Kuo‐Cheng Wu, et al.
  Pubblicazione: (2025)
• Letter: Methodological Considerations in Interpreting Polygenic Risk Scores for Hepatocellular Carcinoma After SVR . Authors' Reply
  di: Yu‐Sheng Lin, et al.
  Pubblicazione: (2026)